T-2513 hydrochloride

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

T-2513 hydrochloride 

T-2513 hydrochloride 是一种选择性的拓扑异构酶 I (topoisomerase I) 抑制剂。T-2513 hydrochloride 与拓扑异构酶 I-DNA 复合物共价结合并使其稳定，且抑制 DNA 复制和 RNA 合成，最终导致细胞死亡。

T-2513 hydrochloride

T-2513 hydrochloride Chemical Structure

CAS No. : 187793-52-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

T-2513 hydrochloride is a selective topoisomerase I inhibitor. T-2513 hydrochloride binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death[1].

IC50 & Target[1]

Topoisomerase I

 

体外研究
(In Vitro)

SN-38 is the metabolite of T-2513 hydrochloride[1].
T-2513 hydrochloride has a broad cytotoxicity against a range of human tumor cell lines[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: WiDr, HT-29, SK-BR-3, MKN-1, SK-LU-1, LX-1, KB, and HeLaS3 cells
Concentration: 15.1-111.5 ng/mL
Incubation Time: 24 hours
Result: Exhibited cytotoxicity against a panel of human tumor cell lines with GI50s of 32.1, 97.6, 38.6, 15.6, 111.5, 15.1, 34.0, and 50.9 ng/mL for WiDr, HT-29, SK-BR-3, MKN-1, SK-LU-1, LX-1, KB, and HeLaS3 cells, respectively.

体内研究
(In Vivo)

T-2513 hydrochloride (1-100 mg/kg) shows Antitumor Activity against Walker-256 carcinoma[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Rats bearing Walker-256 carcinoma[2]
Dosage: 1, 10, and 100 mg/kg
Administration:
Result: The ED50 was 23 mg/kg.

分子量

485.96

Formula

C25H28ClN3O5
CAS 号

187793-52-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Stephan A Veltkamp, et al. Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. Clin Cancer Res. 2008 Nov 15;14(22):7535-44.

    [2]. S Okuno, et al. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res. 2000 Jun 1;60(11):2988-95.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务